Halozyme Therapeutics, Inc. — FY2011 Form 10-K
Business context and reporting period. This filing covers the fiscal year ended December 31, 2011; the filing also reports unaudited fourth-quarter results. Halozyme is a development-stage biopharmaceutical company focused on extracellular-matrix enzymes. Its Enhanze platform uses rHuPH20 to enable subcutaneous delivery of drugs. Hylenex recombinant was its only marketed product; other programs included ultrafast insulin, PEGPH20 for tumors, HTI-501, and partnered candidates.
Financial performance and position
| Metric | FY2011 | FY2010 |
|---|---|---|
| Total revenue | $56.1 million | $13.6 million |
| Product sales, net | $1.8 million | $0.9 million |
| Collaborative-agreement revenue | $54.3 million | $12.7 million |
| Research and development expense | $57.6 million | $51.8 million |
| Selling, general and administrative expense | $18.1 million | $15.1 million |
| Operating loss | $19.8 million | $54.3 million |
| Net loss | $19.8 million | $53.2 million |
| Net loss per share | $0.19 | $0.56 |
- Revenue rose sharply, but was primarily collaboration-related and included significant nonrecurring items: $18.0 million in upfront fees from ViroPharma and Intrexon, $11.0 million in partner milestones, and $17.1 million recognized after the Baxter Hylenex partnership ended. The filing also records $991,000 of previously deferred product sales; the MD&A reports $18.1 million in total revenue recognition tied to the Hylenex transition.
- The lower annual net loss largely reflects these collaboration and transition-related revenues, rather than established product-sales economics. Research and development spending increased 11%, largely from manufacturing and clinical-trial activity; SG&A increased 20%.
- Fourth-quarter 2011 revenue was $2.4 million and net loss was $18.4 million, compared with $3.6 million revenue and $16.9 million net loss in Q4 2010. The company reported profits in Q2 and Q3 2011, driven by unusual collaboration revenue, but a full-year loss.
- Net cash used in operations was $34.4 million in 2011 versus $45.4 million in 2010. Cash and cash equivalents were $52.8 million at year-end, down from $83.3 million. Working capital was $46.7 million; total assets were $65.8 million and total liabilities $54.9 million. The company reported no long-term debt.
- After year-end, the company raised approximately $81.8 million in a February 2012 stock offering, net of underwriting discounts and commissions but before other expenses. Shares outstanding were 103.99 million at year-end and 112.09 million as of March 1, 2012.
- No meaningful operating margin trend is evident from these figures: reported revenue was collaboration-heavy while research and development and SG&A remained substantial. Product-sales gross margin was not a useful indicator of overall performance.
Material changes, outlook and risks
- Halozyme and Baxter ended the Hylenex marketing partnership in January 2011. Following FDA acceptance of requested information, Hylenex was reintroduced in December 2011, with Halozyme assuming sales and distribution responsibilities. Sales revenue is recognized when distributor sell-through can be established; shipments remain deferred until then.
- The company forecast 2012 net cash burn of approximately $50–55 million and said year-end cash was expected to fund operations for at least 12 months. It expected R&D and SG&A to rise as clinical programs advanced and Hylenex marketing expanded; revenue was not expected to fund operations for several years. No profitability guidance was provided.
- Clinical progress included positive reported Phase 2 ultrafast-insulin results, ongoing Phase 1 and Phase 2 PEGPH20 studies, and a Phase 1/2 HTI-501 study. Partner Roche reported positive top-line Phase 3 results for subcutaneous Herceptin; subcutaneous MabThera was in Phase 3. These remained development or regulatory outcomes, not assured commercial revenue.
- Revenue and receivables were concentrated among partners: Roche and Baxter accounted for 19% and 42% of 2011 revenue, respectively; ViroPharma and Intrexon contributed 22% and 16%. Partners can generally terminate agreements on 90 days’ notice, and milestone, reimbursement and royalty revenue is uncertain.
- Key risks include continued losses and cash consumption; dependence on additional financing; clinical-trial failure or regulatory delay; reliance on contract manufacturers and suppliers for rHuPH20 and Hylenex; partner performance and concentration; limited Hylenex sales history and product-return estimation; competition, reimbursement and pricing pressure; and intellectual-property challenges. A European patent opposition was withdrawn in March 2012, but the company said the scope of resulting protection remained uncertain.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions on the financial statements and internal controls. No material legal proceeding was reported; Baxter’s breach claims were discharged under the transition agreement.
Important facts for investors to verify
- How much of reported revenue and future cash inflow is recurring versus upfront, milestone, deferred-revenue recognition, or other one-time items?
- Whether the 2012 $50–55 million cash-burn estimate, post-offering liquidity, and stated operating runway hold as clinical and manufacturing spending develops.
- Hylenex sell-through, returns and chargebacks, commercial uptake, and the successful transition to a new fill-and-finish supplier before the Baxter arrangement expires.
- Clinical, regulatory and partner milestones for ultrafast insulin, PEGPH20, HTI-501, and Roche, Baxter, and ViroPharma programs—and the timing and conditions of any associated payments.
- Manufacturing capacity and quality at Avid, Cook and other suppliers, partner concentration, and any changes in collaboration commitments or target rights.